Related references
Note: Only part of the references are listed.Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies
D. A. Drossman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome
A. W. Mangel et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients
Allen W. Mangel et al.
DIGESTION (2008)
Novel pharmacology:: asimadoline, a κ-opioid agonist, and visceral sensation
M. Camilleri
NEUROGASTROENTEROLOGY AND MOTILITY (2008)
Irritable bowel syndrome
Emeran A. Mayer
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome
S. M. Leventer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Efficacy of on-demand asimadoline, a peripheral k-opioid agonist, in females with irritable bowel syndrome
Lawrence A. Szarka et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation
J Tack et al.
GUT (2005)
Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey
EB Andrews et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Effect of asimadoline, a κ opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome
M Delvaux et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
A model for chronic quantitative studies of colorectal sensitivity using balloon distension in conscious mice - effects of opioid receptor agonists
M Larsson et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2003)
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome
J Kellow et al.
GUT (2003)
The economic impact of irritable bowel syndrome in a managed care setting
RP Patel et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2002)
Functional gastrointestinal disorders in Canada - First population-based survey using Rome II criteria with suggestions for improving the questionnaire
WG Thompson et al.
DIGESTIVE DISEASES AND SCIENCES (2002)
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
M Camilleri et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial
M Camilleri et al.
LANCET (2000)
The impact of irritable bowel syndrome on health-related quality of life
IM Gralnek et al.
GASTROENTEROLOGY (2000)
Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man
HJ Kramer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
